Ivosidenib was also recently approved in combination with azacitidine as frontline therapy in patients with IDH1-mutated AML who are ineligible for intensive chemotherapy based on results of the phase III AGILE trial (6). This evidence concerns the gene IDH1 and acute myeloid leukemia.